The News Forum to Exclusively Air Ground-breaking Documentary 'Fixing Canada's Health Care: Lessons from Japan'
A central revelation of the film is the astonishment expressed by Japanese interviewees when informed that Canadians often endure year-long waits for common surgeries such as knee and hip operations. In stark contrast, patients in Japan can typically receive these procedures within a couple of weeks. The documentary explores two major systemic differences between the two countries that contribute to this disparity, offering valuable insights for the ongoing discussion about healthcare reform in Canada.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
11 hours ago
- Toronto Star
Carestream Announces Improvements to Affordable, Digital-Ready Horizon X-ray System
Rochester, N.Y., Aug. 06, 2025 (GLOBE NEWSWIRE) — Carestream Health today announced the addition of a new, six-way floating table for its Horizon X-ray System—helping provide significant benefits to patient positioning, workflow efficiency, and overall image quality. The ergonomic table helps elevate the system's functionality to help deliver a more user-friendly imaging experience for radiology staff and faster, more comfortable exams for patients.
Toronto Star
15 hours ago
- Toronto Star
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration1 AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults1 This approval marks an important step in expanding the impact of AJOVY beyond adults since its U.S. approval in 2018, and underscores Teva's ongoing efforts to advance and address neurological challenges2 PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. With this approval, AJOVY becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of episodic migraine in pediatric patients and migraine in adults, marking a meaningful advancement in expanding preventive treatment options for those living with migraine.
Toronto Star
2 days ago
- Toronto Star
Yatiri Bio Acquires NGeneBioAI to Expand AI-Powered Proteomics Platform and Advance Precision Biomarker Discovery
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Yatiri Bio, Inc., a leader in proteomics-driven precision medicine, today announced the successful acquisition of NGeneBioAI, Inc., a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition strengthens Yatiri Bio's position at the forefront of biomarker discovery and translational drug development. The transaction includes the transfer of all NGeneBioAI assets, proprietary technologies, commercial agreements, and intellectual property in accordance with applicable agreements. As part of the deal, Yatiri Bio issued common stock to NGeneBio, the parent company of NGeneBioAI.
